Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3050258 · 2 trials · 2 indications
Clinically significant events were defined as serious and other nonserious adverse events (AE) related to study drug. A summary of other nonserious AEs, and all SAE's, regardless of causality, is located in the Reported Adverse Events section.
| Arm | Type | Description |
|---|---|---|
| LY3050258 | EXPERIMENTAL | Daily dose of LY3050258 for 28 days: Cohort A 10 mg, Cohort B 30 mg, Cohort C 90 mg, Cohort D 180 mg and Cohort E 360 mg. |
| Placebo | PLACEBO_COMPARATOR | Daily dose of placebo matching LY3050258 for 28 days. |
| Name | Type | Description |
|---|---|---|
| LY3050258 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Healthy males or healthy postmenopausal females, including Japanese participants * Body mass index (BMI) of 18 and 35 kilograms per square meter (kg/m\^2), inclusive Exclusion Criteria: * Abnormal siting blood pressure as determined by the investigator * Abnormality in the 1...
LY3050258 is an investigational small molecule being developed by Eli Lilly and Company. It has been studied in Phase 1 clinical trials in healthy participants. The specific disease or condition it is intended to treat has not been publicly disclosed.
LY3050258 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker symbol LLY. Lilly is the sponsor of the clinical trials conducted for this compound.
LY3050258 is in Phase 1 clinical development. Two Phase 1 trials have been completed, and no active trials are currently listed. The program remains investigational and has not been approved by the FDA.
LY3050258 has been evaluated in two completed Phase 1 trials: NCT02121834, which enrolled 63 healthy participants, and NCT01929707, which enrolled 38 healthy participants. Both were conducted in the United States and together enrolled 101 participants.
Both Phase 1 trials of LY3050258 were randomized, double-blind, and placebo-controlled studies in healthy participants aged 30 years and older. NCT02121834 enrolled 63 participants and NCT01929707 enrolled 38, for a combined total of 101.